http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Da Wun Jeong ),( Ju Young Moon ),( Sang Ho Lee ),( Yang Gyun Kim ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Plasma levels of cell-free DNA (cfDNA) are elevated in various proin- fi ammatory or apoptotic conditions. Previously, increased cfDNA levels were reported during hemodialysis. However, there is limited data regarding its clinical relevance in HD patients. The aim of this study was to investigate the clinical signifi cance of cfDNA in patients on maintenance HD. Methods: A total of 95 ESRD patients on Hemodialysis for 49.6±52.4 months were enrolled, we measured the pre-dialysis cfDNA using real-time EIF2C1 gene sequence amplifi cation and analyzed the association with clinical parameters by dividing to cfDNA <2000GE/ml, 2000< cfDNA<3000GE/ml and >3000 GE/ml with underlying disease and higher cfDNA and baseline characteristics and clinical parameters with cfDNA. Results: The mean plasma level of cfDNA of HD patients was 2302.07±2177.52GE/ mL and the mean plasma level of cfDNA of control group was 1420.74±1216.44GE/ mL( p< 0.05). cfDNA levels were signifi cantly higher in patients with diabetes mellitus compared to non-diabetic patients (2214.5±2163.4 vs. 1452.6±1221.3GE/mL, respectively, p < 0.035). CfDNA was signifi cantly correlated with current HbA1c but not associated with those of other time points. Patients with previous history of cerebrovascular disease, hypertension had also higher levels of cfDNA. Among clinical parameters, systolic blood pressure, current WBC counts were signifi cantly correlated with the levels of cfDNA but there was no association with infi ammatory parameters of different time points. finally, other parameters of dialysis adequacy including KT/V, uric acid and Ca, Ca*P, hemoglobin, LDL, age, BMI were not associated with the plasma levels of cfDNA. Conclusions: Our results indicate cfDNA could be a potential biomarker of proin- fi ammatory or apoptotic milieu in maintenance HD patients. However, the underlying reasons for the release of cfDNA and its functional role in uremic condition should be further defi ned for its clinical application.
Effect of blood pressure and glycemic control on the plasma cell-free DNA in hemodialysis patients
( Da Wun Jeong ),( Ju Young Moon ),( Young Wook Choi ),( Haena Moon ),( Kipyo Kim ),( Yu Ho Lee ),( Se Yeun Kim ),( Yang Gyun Kim ),( Kyung Hwan Jeong ),( Sang Ho Lee ) 대한신장학회 2015 Kidney Research and Clinical Practice Vol.34 No.4
Background: The plasma levels of cell-free DNA (cfDNA) are known to be elevated under inflammatory or apoptotic conditions. Increased cfDNA levels have been reported in hemodialysis (HD) patients. The aim of this study was to investigate the clinical significance of cfDNA in HD patients. Methods: A total of 95 patients on HD were enrolled. We measured their predialysis cfDNA levels using real-time EIF2C1 gene sequence amplification and analyzed its association with certain clinical parameters. Results: The mean plasma cfDNA level in the HD patients was 3,884 ± 407 GE/mL, and the mean plasma cfDNA level in the control group was 1,420 ± 121 GE/mL (P < 0.05). Diabetic patients showed higher plasma cfDNA levels compared with nondiabetic patients (P < 0.01). Patients with cardiovascular complications also showed higher plasma cfDNA levels compared with those without cardiovascular complication (P < 0.05). In univariable analysis, the cfDNA level was associated with 3-month mean systolic blood pressure (SBP), white blood cell, serum albumin, creatinine (Cr), normalized protein catabolic rate in HD patients. In diabetic patients, it was significantly correlated with SBP, hemoglobin A1c, and serum albumin. In multivariate analysis, SBP was the independent determinant for the cfDNA level. In diabetic patients, cfDNA level was independently associated with hemoglobin A1c and SBP. Conclusions: In patients with HD, cfDNA is elevated in diabetic patients and patients with cardiovascular diseases. Uncontrolled hypertension and poor glycemic control are independent determinants for the elevated cfDNA. Our data suggest that cfDNA might be a marker of vascular injury rather than proinflammatory condition in HD patients.
Yang, Da-Wun,Kang, Ok-Hwa,Lee, Young-Seob,Han, Sin-Hee,Lee, Sang-Won,Cha, Seon-Woo,Seo, Yun-Soo,Mun, Su-Hyun,Gong, Ryong,Shin, Dong-Won,Kwon, Dong-Yeul Spandidos Publications 2016 International journal of molecular medicine Vol.38 No.6
<P>Salidroside [2-(4-hydroxyphenyl)ethyl beta-D-glucopyranoside (SAS)] has been identified as the most potent ingredient of the plant Rhodiola rosea L. Previous studies have demonstrated that it possesses a number of pharmacological properties, including anti-aging, anti-fatigue, antioxidant, anticancer and anti-inflammatory properties. In this study, to ascertain the molecular mechanisms responsible for the anti-inflammatory activity of SAS, we used phorbol-12-myristate-13-acetate (PMA) plus A23187 to induce inflammation in human mast cell line-1 (HMC-1). The HMC-1 cells were treated with SAS prior to being stimulated with PMA plus A23187. Pro-inflammatory cytokine production was measured by enzyme-linked immunosorbent assay (ELISA) and reverse transcription-polymerase chain reaction (RT-PCR). Western blot analysis was used to examine the activation of mitogen-activated protein kinases (MAPKs) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B). SAS inhibited the mRNA expression and production of interleukin (IL)-6, IL-8 and tumor necrosis factor (TNF). In cells stimulated with PMA plus A23187, SAS suppressed the phosphorylation of extracellular signal-regulated kinase (ERK)1/2 and c-jun N-terminal kinase 1/2 (JNK1/2), but not that of p38 MAPK. SAS suppressed the expression of NF-kappa B in the nucleus. On the whole, our results suggest that SAS exerts an anti-inflammatory effect by inhibiting the production of pro-inflammatory cytokines through the blocking of the NF-kappa B and MAPK signaling pathways.</P>
Kwon, Da Hye,Cha, Hee-Jae,Choi, Eun Ok,Leem, Sun-Hee,Kim, Gi-Young,Moon, Sung-Kwon,Chang, Young-Chae,Yun, Seok-Joong,Hwang, Hye Jin,Kim, Byung Woo,Kim, Wun-Jae,Choi, Yung Hyun UNKNOWN 2018 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE Vol.41 No.1
<P>Schisandrin A is a bioactive lignan occurring in the fruits of plants of the <I>Schisandra</I> genus that have traditionally been used in Korea for treating various inflammatory diseases. Although the anti-inflammatory and antioxidant effects of lignan analogues similar to schisandrin A have been reported, the underlying molecular mechanisms have remained elusive. In the present study, schisandrin A significantly suppressed the lipopolysaccharide (LPS)-induced production of the key pro-inflammatory mediators nitric oxide (NO) and prostaglandin E<SUB>2</SUB> by suppressing the expression of inducible NO synthase and cyclooxygenase-2 at the mRNA and protein levels in RAW 264.7 macrophages. Furthermore, schisandrin A was demonstrated to reduce the LPS-induced secretion of pro-inflammatory cytokines, including tumor necrosis factor-α and interleukin-1β; this was accompanied by a simultaneous decrease in the respective mRNA and protein levels in the macrophages. In addition, the LPS- induced translocation of nuclear factor-κB (NF-κB), as well as activation of mitogen-activated protein kinases (MAPKs) and phosphatidylinositol-3 kinase (PI3K)/Akt pathways were inhibited by schisandrin A. Furthermore, schisandrin A significantly diminished the LPS-stimulated accumulation of intracellular reactive oxygen species, and effectively enhanced the expression of NF erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1). These results suggested that schisandrin A has a protective effect against LPS-induced inflammatory and oxidative responses in RAW 264.7 cells by inhibiting the NF-κB, MAPK and PI3K/Akt pathways; these effects are mediated, at least in part, by the activation of the Nrf2/HO-1 pathway. Based on these results, it is concluded that schisandrin A may have therapeutic potential for treating inflammatory and oxidative disorders caused by over-activation of macrophages.</P>
정다은 ( Da Wn Chung ),( Yoo Jin Lee ),( Mi Hyun Jo ),( Hyun Jong Park ),( Ga Won Lim ),( Hanbyoul Cho ),( Eun Ji Nam ),( Sang Wun Kim ),( Jae Hoon Kim ),( Young Tae Kim ),( Sung Hoon Kim ) 대한산부인과학회 2014 대한산부인과학회 학술대회 Vol.100 No.-
Objective: The goal of this study was to compare postoperative surgical site pain in gynecologic cancer patients who underwent elective extended lower midline laparotomy and managed their pain with either the ON-Q pain management system (surgical incision site pain relief system, ON-Q pump) or an intravenous patient-controlled analgesia pump (IV PCA). Methods: Twenty gynecologic cancer patients who underwent elective extended lower midline laparotomy were divided into two groups. One group received a 72-hour continuous wound perfusion of the local anesthetic ropivacaine (0.5%, study group) into the supraperitoneal layer of the abdominal incision through the ON-Q pump. The other group received intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL ? kg+ondansetron hydrochloride 16 mg/8 mL+normal saline). Postoperative pain was assessed immediately and at 6, 24, 48, 72, and 96 hours after surgery using the visual analogue scale. Results: Postoperative surgical site pain scores at 24, 48, and 72 hours after surgery were lower in the ON-Q group than the IV PCA group. Pain scores at 24 hours and 48 hours after surgery were significantly different between the two groups (P = 0.023, P<0.001). Overall painkiller administration was higher in the ON-Q group but this difference was not statistically significant (5.1 vs. 4.3, P = 0.481). Conclusion: This study revealed that the ON-Q pain management system is a more effective approach than IV PCA for acute postoperative surgical site pain relief after extended lower midline laparotomy in gynecologic cancer patients.
이민혜,정다운,최미용,이승희 숙명여자대학교 건강·생활과학연구소 2009 生活科學硏究誌 Vol.- No.25
India is a new and popular marker for doing businesses. According to the Kotra and Samsung Economy Research Center, 40% of demands in India hold watch market and it occupies the top. With this data, this research chooses India for the proper market and to deal with unexpected situations, a new brand, Veritas, starts the business directly. In more depth, to enter the foreign market, this research is based on SWOT Strategy, STP, 4P and other marketing thesis. For the final strategies, this research focuses on weaknesses and threats. These points will be solved by the researcher's suggestions. Concretely, because of the special quality of the target market, India, researchers will focus on cultures and religions to develop business strategies. Furthermore, both of localization and globalization will be used.